We are failing
As scientists, we are failing society in coming up with effective treatments for neurodegenerative disorders.
With a drug failure
rate of 94 %...

it is time to rethink the scientific approach of neurodegenerative disease research.

Since 2003...

no new drug has been approved for the treatment of Alzheimer’s Disease, with more than 400 failed clinical trials.

The standard single molecule approach has failed...

for the past 20 years we have been targeting one central mechanism...out of many.

This is why we founded Actipulse Neuroscience®

We are a neuro-tech company specialized in the research and engineering of Non-Invasive Brain Stimulation technologies for the treatment of Parkinson’s Disease and dementia.

We are pioneers in Non Invasive Brain Stimulation technologies with a particular focus on transcranial neuromodulation devices using high frequency magnetic pulses that target multiple well known, but neglected pathogenic mechanisms in neurodegenerative disorders.

Current Clinical Pipeline

Actipulse Neuroscience is focused on leading world class research with a particular emphasis on respecting the highest clinical and ethical standards. We have currently various basic and phase 3 clinical trials running, most notable on Mild Cognitive Impairment and Parkinson’s Disease
for clinical and home based treatments.

  • Pre-clinical Parkinson’s Disease

    Ongoing

  • Clinical trial Parkinson´s Disease

    Waiting for IRB approval

  • Pre-clinical Alzheimer’s Disease

    Waiting for IRB approval

  • Clinical trial Alzheimer’s Disease

    Currently running *

* ClinicalTrials.gov Identifier: NCT03983655

The future golden standard of neurodegenerative treatment

The latest scientific literature and our current clinical results are showing that the future of neurological treatments will be a combination of pharmacological drugs targeting defined mechanisms such as Peptide deposition, excitotoxicity and metabolic targets and neuromodulation therapy treating loss of plasticity, loss of neurogenesis and inflammation.

Actipulse Neuroscience has for goal to be the golden standard of neuromodulation technologies in the next five years and to become an integral part of the treatment of the millions of patients suffering from Parkinson’s Disease and dementia in the world.

Contact us
Actipulse Neuroscience, Inc.

Global Headquarters
210 Broadway,
Cambridge, MA

Phone: 1-617-420 4312

Actipulse International SA de CV

Latin America HQ
Nuevo Leon 202
Mexico City

Phone: 55 4624 45 29

Actipulse Chile SRL

South America HQ
Av. Nueva Providencia, 1881
Santiago de Chile

Phone: 56 99543 9298